Xynomic Pharmaceuticals Holdings Inc.'s abexinostat received the U.S. Food and Drug Administration's fast-track status to treat follicular lymphoma that has returned or is resistant to treatment.
![]() |
The Cheyenne, Wyo.-based biotechnology company is studying the medicine as a fourth-line treatment of relapsed or refractory follicular lymphoma, a cancer of white blood cells responsible for fighting infections.
The cancer affects about 14,840 people each year in the U.S. and often requires multiple lines of treatment. The disease usually returns less than one year after a patient receives their third line of treatment.
The FDA previously granted fast-track designation to a combination of abexinostat and pazopanib as a first- or second-line treatment of kidney cancer.

